Biocon gets European Commission nod for breast cancer biosimilar
8 outletsin 1 language and 1 countryFirst reported , latest
Every report 10 reports
- Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio
biospectrumindia.com
Add to CRMAlso published by biospectrumindia.com, biospectrumindia.com
- Biocon gets European Commission nod for breast cancer biosimilar Pebrilzo
Daily ExcelsiorIN
Add to CRMAlso published by Mint
- Biocon Gets US FDA Approval For Pebrilzo Breast Cancer Drug, Plans US Launch In 2028
The Free Press JournalIN
Add to CRM